Published in Am J Hematol on February 01, 2005
A review of the literature on the multiple dimensions of chronic pain in adults with sickle cell disease. J Pain Symptom Manage (2010) 1.08
Daily assessment of pain in adults with sickle cell disease. Ann Intern Med (2008) 3.81
Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol (2002) 3.25
Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med (2008) 3.22
Palliative care benchmarks from academic medical centers. J Palliat Med (2007) 2.34
Providing pain and palliative care education internationally. J Support Oncol (2011) 2.04
Reoperation 10 years after surgically managed pelvic organ prolapse and urinary incontinence. Am J Obstet Gynecol (2008) 2.01
Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes (2005) 1.93
Pain assessment in the nonverbal patient: position statement with clinical practice recommendations. Pain Manag Nurs (2006) 1.92
Pain assessment in the patient unable to self-report: position statement with clinical practice recommendations. Pain Manag Nurs (2011) 1.64
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood (2008) 1.61
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
Transient exposure of mammary tumors to PD184352 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Cancer Biol Ther (2005) 1.46
Do African American men have lower survival from prostate cancer compared with White men? A meta-analysis. Am J Mens Health (2010) 1.44
When cancer pain breaks through, what can you do? Oncology (Williston Park) (2010) 1.40
A case of inaccurate prognostication after the ARCTIC protocol. J Pain Symptom Manage (2012) 1.39
Pilot trial of a patient-specific cutaneous electrostimulation device (MC5-A Calmare®) for chemotherapy-induced peripheral neuropathy. J Pain Symptom Manage (2010) 1.39
Depression and anxiety in adults with sickle cell disease: the PiSCES project. Psychosom Med (2007) 1.29
Recruiting African-American barbershops for prostate cancer education. J Natl Med Assoc (2008) 1.28
Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial. Contemp Clin Trials (2011) 1.28
RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys (2003) 1.26
Gender differences in pain and healthcare utilization for adult sickle cell patients: The PiSCES Project. J Womens Health (Larchmt) (2006) 1.16
Pain site frequency and location in sickle cell disease: the PiSCES project. Pain (2009) 1.10
Understanding pain and improving management of sickle cell disease: the PiSCES study. J Natl Med Assoc (2005) 1.10
Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage (2010) 1.09
Arachidonic acid stimulates cell adhesion through a novel p38 MAPK-RhoA signaling pathway that involves heat shock protein 27. J Biol Chem (2009) 1.06
A controlled trial of universal gloving versus contact precautions for preventing the transmission of multidrug-resistant organisms. Am J Infect Control (2007) 1.02
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res (2011) 1.02
Somatic symptom burden in adults with sickle cell disease predicts pain, depression, anxiety, health care utilization, and quality of life: the PiSCES project. Psychosomatics (2011) 1.01
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol (2003) 1.00
Opioid patient controlled analgesia use during the initial experience with the IMPROVE PCA trial: a phase III analgesic trial for hospitalized sickle cell patients with painful episodes. Am J Hematol (2011) 1.00
Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther (2007) 0.99
A trial of Scrambler therapy in the treatment of cancer pain syndromes and chronic chemotherapy-induced peripheral neuropathy. J Pain Palliat Care Pharmacother (2013) 0.98
15S-Lipoxygenase-2 mediates arachidonic acid-stimulated adhesion of human breast carcinoma cells through the activation of TAK1, MKK6, and p38 MAPK. J Biol Chem (2005) 0.98
Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol (2007) 0.97
IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies. Clin Trials (2013) 0.96
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs (2010) 0.93
Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study. J Natl Med Assoc (2007) 0.92
Achieving durable glucose control in the intensive care unit without hypoglycaemia: a new practical IV insulin protocol. Diabetes Metab Res Rev (2007) 0.91
The role of catastrophizing in sickle cell disease--the PiSCES project. Pain (2007) 0.91
Requirement of protein kinase C micro activation and calpain-mediated proteolysis for arachidonic acid-stimulated adhesion of MDA-MB-435 human mammary carcinoma cells to collagen type IV. J Biol Chem (2003) 0.90
Probing molecular shape. 1. Conformational studies of 5-hydroxyhexahydropyrimidine and related compounds. J Org Chem (2007) 0.89
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther (2008) 0.88
A randomized, placebo controlled trial of oral zinc for chemotherapy-related taste and smell disorders. J Pain Palliat Care Pharmacother (2012) 0.87
Frequency and management of breakthrough bleeding with continuous use of the transvaginal contraceptive ring: a randomized controlled trial. Obstet Gynecol (2008) 0.87
Conformational equilibria of ethanolamine and its hydrochloride in solution. Org Lett (2007) 0.86
Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. Cancer (2002) 0.86
Quantum-mechanical calculations of the stabilities of fluxional isomers of C4H(7)(+) in solution. Proc Natl Acad Sci U S A (2002) 0.86
Inter-alpha-trypsin inhibitor promotes bronchial epithelial repair after injury through vitronectin binding. J Biol Chem (2009) 0.86
Messages in molecules: ligand/cation coding and self-recognition in a constitutionally dynamic system of heterometallic double helicates. Chemistry (2006) 0.85
Health decision-making preferences among African American men recruited from urban barbershops. J Natl Med Assoc (2009) 0.85
Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. J Palliat Med (2011) 0.85
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol (2012) 0.84
Palliative care consultation in the process of organ donation after cardiac death. J Palliat Med (2007) 0.84
The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat (2003) 0.84
Using age-based life history data to investigate the life cycle and vulnerability of Octopus cyanea. PLoS One (2012) 0.84
Emerging biobehavioral factors of fatigue in sickle cell disease. J Nurs Scholarsh (2011) 0.84
Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Sci (2012) 0.84
Lysine 63-linked ubiquitination is important for arachidonic acid-induced cellular adhesion and migration. Biochem Cell Biol (2010) 0.83
P-selectin activates integrin-mediated colon carcinoma cell adhesion to fibronectin. Exp Cell Res (2006) 0.83
Conformational preferences of 3-(dimethylazinoyl)propanoic acid as a function of pH and solvent; intermolecular versus intramolecular hydrogen bonding. J Org Chem (2009) 0.82
Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location. Am J Hematol (2010) 0.82
Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs (2013) 0.82
How to use implantable intrathecal drug delivery systems for refractory cancer pain. J Support Oncol (2004) 0.82
Nurses' perceptions of educational gaps in delivering end-of-life care. Oncol Nurs Forum (2011) 0.81
Pain management issues for cancer survivors. Cancer Pract (2002) 0.81
An NMR and quantum-mechanical investigation of tetrahydrofuran solvent effects on the conformational equilibria of 1,4-butanedioic acid and its salts. J Am Chem Soc (2002) 0.81
ABH gel is not absorbed from the skin of normal volunteers. J Pain Symptom Manage (2012) 0.81
Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med (2005) 0.81
Timeliness of immunizations of children in a Medicaid primary care case management managed care program. J Natl Med Assoc (2002) 0.80
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res (2013) 0.80
A novel role for the T-box transcription factor Tbx1 as a negative regulator of tumor cell growth in mice. Mol Carcinog (2011) 0.79
Conformational equilibria of N,N-dimethylsuccinamic acid and its lithium salt as a function of solvent. Org Lett (2013) 0.79
Expanding the framework of assessing adherence and medication-taking behavior. J Pain Palliat Care Pharmacother (2013) 0.79
The relationship between taste, olfaction, and nutrition in the cancer population. J Support Oncol (2009) 0.78
Alcohol abuse in sickle cell disease: the Pisces Project. Am J Addict (2007) 0.78
15-lipoxygenase-1 activates tumor suppressor p53 independent of enzymatic activity. Int J Cancer (2008) 0.78
Arachidonic acid stimulates formation of a novel complex containing nucleolin and RhoA. FEBS Lett (2011) 0.78
Intramolecular hydrogen bonding in disubstituted ethanes: general considerations and methodology in quantum mechanical calculations of the conformational equilibria of succinamate monoanion. J Phys Chem A (2005) 0.78
Pain in sickle cell disease: the future of acute treatment. Expert Rev Hematol (2011) 0.77
Phase I studies of weekly administration of cytotoxic agents: implications of a mathematical model. Invest New Drugs (2003) 0.77
Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes. Am J Hematol (2012) 0.77
Pain management, including intrathecal pumps. Curr Oncol Rep (2004) 0.77
Nebulized lidocaine for intractable cough near the end of life. J Support Oncol (2007) 0.77
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Mol Pharmacol (2006) 0.77
Referral patterns for syndromes associated with frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord (2005) 0.77
Development of a sickle cell disease readiness for transition assessment. Int J Adolesc Med Health (2016) 0.76
Safe use of opioids to manage pain in patients with cirrhosis. Mayo Clin Proc (2010) 0.76
An NMR investigation of the importance of intramolecular hydrogen bonding in determining the conformational equilibrium of ethylene glycol in solution. Magn Reson Chem (2005) 0.76
Self-efficacy and readiness for transition from pediatric to adult care in sickle cell disease. Int J Adolesc Med Health (2016) 0.76
Methadone-related Torsades de Pointes in a sickle cell patient treated for chronic pain. Am J Hematol (2005) 0.76
Faculty values. J Gen Intern Med (2010) 0.75